What 16 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Portfolio Pulse from Benzinga Insights
Biomarin Pharmaceutical (NASDAQ:BMRN) has received a mix of bullish, somewhat bullish, and indifferent ratings from 16 analysts over the last quarter. The average 12-month price target for the company is $110.94, representing a 4.26% decrease from the previous average price target of $115.88.
September 13, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biomarin Pharmaceutical has received mixed analyst ratings, with an average 12-month price target of $110.94, a decrease from the previous target.
The mixed analyst ratings indicate uncertainty about the company's performance. The decrease in the average price target suggests that analysts have lowered their expectations for the company's stock price, which could potentially impact investor sentiment and the stock's price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100